Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KontRASt-06 JDQ443 first-line NSCLC trial
NL-OMON53674Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of opnurasib in non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoint: Overall response rate by BIRC. Started Jul 2023; status: recruiting.
02
Drugs
opnurasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON53674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53674.